Subarachnoid Hemorrhage Pipeline Summary

DelveInsight’s, “Subarachnoid Hemorrhage - Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Subarachnoid Hemorrhage pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Subarachnoid Hemorrhage: Understanding

Subarachnoid Hemorrhage: Overview

Subarachnoid hemorrhage (SAH) is a life-threatening form of hemorrhagic stroke characterized by bleeding into the subarachnoid space between the arachnoid membrane and pia mater, where cerebrospinal fluid and cerebral blood vessels are located. Approximately 85% of nontraumatic SAH cases result from rupture of an intracranial aneurysm, while the remainder are associated with nonaneurysmal or other vascular causes.

SAH may be traumatic or nontraumatic in origin. Among nontraumatic cases, aneurysmal rupture is the predominant cause. Important risk factors for aneurysm formation and rupture include hypertension, cigarette smoking, family history of aneurysm or SAH, alcohol use, sympathomimetic drug exposure, older age, atherosclerosis, and certain inherited conditions such as autosomal dominant polycystic kidney disease. Other causes include perimesencephalic nonaneurysmal SAH, vascular malformations such as arteriovenous malformations, intracranial arterial dissection, cerebral venous thrombosis, vasculitis, bleeding disorders, and cerebral amyloid angiopathy.

Intracranial aneurysm formation is initiated by hemodynamic stress on arterial walls, particularly at arterial bifurcations and junctions. Increased vascular stress can trigger inflammation, matrix metalloproteinase-mediated degradation of the extracellular matrix, and apoptosis of vascular smooth muscle cells, progressively weakening the arterial wall and promoting aneurysm formation and rupture. Following rupture, blood enters the subarachnoid space and can cause reduced cerebral blood flow, vasospasm, cerebral ischemia, hydrocephalus, and delayed cerebral ischemia.

The characteristic clinical presentation is a sudden, severe thunderclap headache, often described as the “worst headache of my life,” which may be accompanied by nausea, vomiting, neck stiffness, photophobia, neurological deficits, or loss of consciousness. Initial evaluation generally involves a noncontrast head CT. If SAH is identified, CT angiography is used to locate and characterize a potential aneurysm. When CT is negative despite strong clinical suspicion, lumbar puncture can be performed to detect cerebrospinal-fluid abnormalities such as xanthochromia. If CT angiography does not identify an aneurysm, cerebral angiography or digital subtraction angiography may be required.

Management of SAH focuses on preventing rebleeding, securing the ruptured aneurysm, preventing delayed cerebral ischemia, and providing supportive care. For aneurysmal SAH, definitive treatment generally involves either endovascular coiling or surgical clipping of the aneurysm. Medical management and intensive monitoring are also important for complications such as vasospasm, hydrocephalus, seizures, pain, and increased intracranial pressure.

"Subarachnoid Hemorrhage- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Subarachnoid Hemorrhage pipeline landscape is provided which includes the disease overview and Subarachnoid Hemorrhage treatment guidelines. The assessment part of the report embraces, in depth Subarachnoid Hemorrhage commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Subarachnoid Hemorrhage collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Subarachnoid Hemorrhage R&D. The therapies under development are focused on novel approaches to treat/improve Subarachnoid Hemorrhage.

Subarachnoid Hemorrhage Emerging Drugs Chapters

This segment of the Subarachnoid Hemorrhage report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Subarachnoid Hemorrhage Emerging Drugs

• EDV2209: Edvince AB

EDV2209 is a proprietary drug which acts by inhibiting the activation (phosphorylation) of MEK1/2 and ERK1/2, thereby blocking the downstream transcriptional cascade that increases vasoconstrictive receptors and inflammatory molecules in cerebral artery smooth-muscle cells. By preventing this vascular response, EDV2209 is designed to stabilize vascular function, improve microcirculatory blood flow and oxygen delivery, reduce endothelial dysfunction, oxidative stress and inflammation, and ultimately reduce delayed cerebral ischemia (DCI) following SAH. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Subarachnoid Hemorrhage.

• RSLV-145: Resolve Therapeutics

RSLV-145 is a fully human, dual-action preclinical fusion protein consisting of catalytically active DNase and RNase enzymes fused to an optimized human IgG1 Fc region. It is designed to remain in the circulation and enzymatically digest extracellular pathogenic nucleic acids, including cell-free DNA (cfDNA) and cell-free RNA (cfRNA). In subarachnoid hemorrhage (SAH), the removal of circulating cfRNA is intended to reduce the inflammatory response triggered by these pathogenic nucleic acids, thereby decreasing the extent of brain injury following hemorrhage. Resolve is also developing RSLV-145 for ischemic stroke, where its DNase activity is intended to degrade neutrophil extracellular traps (NETs) that can interfere with tissue plasminogen activator (tPA) activity. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Subarachnoid Hemorrhage.

Further product details are provided in the report……..

Subarachnoid Hemorrhage: Therapeutic Assessment

This segment of the report provides insights about the different Subarachnoid Hemorrhage drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Subarachnoid Hemorrhage

There are approx. 10+ key companies which are developing the therapies Subarachnoid Hemorrhage. The companies which have their Subarachnoid Hemorrhage drug candidates in the most advanced stage, i.e. Phase I/II include, Edvince and others.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Subarachnoid Hemorrhage pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Subarachnoid Hemorrhage: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Subarachnoid Hemorrhage therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Subarachnoid Hemorrhage drugs.

Subarachnoid Hemorrhage Report Insights

• Subarachnoid Hemorrhage Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Subarachnoid Hemorrhage Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Subarachnoid Hemorrhage drugs?
• How many Subarachnoid Hemorrhage drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Subarachnoid Hemorrhage?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Subarachnoid Hemorrhage therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Subarachnoid Hemorrhage and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Edvince
• Resolve Therapeutics
• Grace Therapeutics
• Qanat Pharma

Key Products

• EDV2209
• RSLV-145
• RSLV-132
• GTX-104
• QP-238